Best Practices in Transfusion Medicine for Patients with Sickle Cell Disease

镰状细胞病患者输血医学的最佳实践

• 批准号: 7330268
• 负责人: Theodore Wun
• 金额: $ 2万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-15 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7330268
• 关键词: Acute; Anemia; Blood flow; Brain; Chronic; Clinical Pathways; Disease; Erythrocyte Transfusion; Erythrocytes; Kidney; Lung; Medicine; Organ; Pathway interactions; Patient Care; Patients; Sickle Cell Anemia; Transfusion; abstracting; improved

DESCRIPTION (provided by applicant): Sickle cell anemia is a disease of the red blood cell that results in anemia and repeated bouts of decreased blood flow to vital organs resulting in progressive damage to many organs including the kidneys, lungs, and brain. The transfusion of red blood cells can ameliorate many of these complications, but can be associated with both acute and chronic complications. The objective of the proposed Best Practices in Transfusion Medicine for Patients with Sickle Cell Disease (SCD) is to develop explicit clinical pathways for the use of red blood cells in SCD patients. Use of these pathways will improve the care for these patients. (End of Abstract)

描述（由申请人提供）： 镰状细胞性贫血是一种红细胞疾病，导致贫血和重要器官血流减少的反复发作，导致许多器官（包括肾脏、肺和大脑）的进行性损伤。输注红细胞可以改善许多这些并发症，但可能与急性和慢性并发症有关。拟议的镰状细胞病（SCD）患者输血医学最佳实践的目的是为SCD患者使用红细胞制定明确的临床路径。使用这些途径将改善对这些患者的护理。(End摘要）